Wednesday, March 06, 2019 8:08:38 AM
1. Multiple Pharm prodrug Patents until 2034
2. Licensing agreements with another Pharm company worth 10's of millions 9/2018
3. Continued verifiable ongoing research in Denmark, Germany, and The USA. 2/2019
4. Military research involvement 11/2018
5. Samuel Denmeade, John Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center, Department of Defense Prostate Cancer Research Program/Military Clinical Pipeline
6. Sabby Hedge fund, Hal Mintz - ownership investment 11/2018
7. JLL one of the world's leading investment managers, Connor Flannery - ownership investment 11/2018
8. Soren Christensen - University of Copenhagen - Continued research latest publication submitted in Dec 2018 Published in January 2019.
9. FDA - Orphan Drug Status for Mipsagargin G-202
10. WHO’s International Nonproprietary Name group or the INN recommended the generic name “mipsagargin” for Inspyr's lead compound G-202
Going to take off with the impending SEC filings!!
NSPX STRONGER
Recent RBSH News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/21/2023 09:19:43 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 08/14/2023 08:36:33 PM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM